

Grifols' XEMBIFY® receives European approvals, expanding access to innovative therapies

- *The company plans to launch XEMBIFY®, its 20% subcutaneous immunoglobulin for primary and secondary immunodeficiencies, in France, Spain and the U.K. as soon as the third quarter of 2022*
- *Grifols solidifies its IG leadership and further expands the innovative reach of its plasma-derived medicines to benefit patients*
- *Already available in the U.S., XEMBIFY® has proven to be safe, efficacious and tolerable and is formulated for a broad range of patients with immunodeficiencies*

Barcelona, Spain, March 10, 2022 - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a leading global producer of plasma-derived medicines, today announced that XEMBIFY®, its innovative 20% subcutaneous immunoglobulin (SCIG), has been approved by several European Union member state health authorities as well as the U.K.'s to treat primary and select secondary immunodeficiencies.

Rollout will begin as soon as the third quarter of 2022 in France, Spain and the U.K. before extending to other European markets. XEMBIFY® availability will provide access to another innovative Grifols IG treatment option where the company already can offer its intravenous IG therapies Gamunex® and Flebogamma®.

Approved indications in Europe for XEMBIFY® include primary immunodeficiencies (PIDD), covering chronic and rare genetic disorders that occur in people born with an impaired or absent immune system. They also cover select secondary immunodeficiencies (SID), when a body's defenses are compromised by environmental factors such as illness or malnutrition.

Just including PIDD patients in Europe, it's estimated that about 27,000 are candidates for IG therapy¹, with SCIG increasingly being used over the intravenous option.

XEMBIFY®, with proven safety, efficacy and tolerability, features a balanced formulation for treating a wide range of patients with immunodeficiencies, including those with risk factors such as diabetes or cardiac impairment. With maximum immunoglobulin G (IgG) potency and purity due to its unique caprylate/chromatography process, XEMBIFY® provides a customizable IG treatment option (daily or weekly) that offers patients reliable protection from infections.

¹ Source: MRB, *Global Usage and Forecast of the Immunoglobulin Market by Region*.

GRIFOLS

“Approval across Europe enables Grifols to expand its innovative European IG product portfolio and provide patients and healthcare professionals with another important treatment option for primary and secondary immunodeficiencies,” said Thierry Heinrich, Vice President of Sales & Commercial, Grifols Bioscience Division, Europe. “We are very pleased to take another step in our continuous work to enhance the lives and well-being of people living with chronic rare diseases.”

The company, a market leader in the production and marketing of immunoglobulins, launched XEMBIFY® in the U.S. in December 2019.

Immunoglobulins are mainly used to treat primary and secondary immunodeficiencies, as well as rare neurological conditions, such as chronic inflammatory demyelinating polyneuropathy (CIDP). Immunoglobulin use continues to grow in major markets. Between 2016-2020, immunoglobulin volume was estimated to have had an average annual growth rate of more than 8%².

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 110 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2021, Grifols’ economic impact in its core countries of operation was EUR 7.7 billion. The company also generated 141,500 jobs, including indirect and induced.

The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols’ non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit www.grifols.com

² Source: *Ibid.*

MEDIA CONTACT:

Media Press Office

media@grifols.com

Tel. +34 571 00 02

INVESTORS:

Investor Relations Department

inversores@grifols.com - investors@grifols.com

Tel. +34 93 571 02 21

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.